'Small-Molecule Cancer Drug Revenues Will Reach $27.3bn in 2015' Predicts visiongain Report

LONDON, November 3, 2011 /PRNewswire/ --

http://www.visiongain.com/Report/708/Small-Molecule-Targeted-Cancer-Therapies-World-Market-2011-2021

A new report by visiongain, a London-based business information company, predicts that small-molecule targeted cancer therapy revenues will reach $27.3bn worldwide in 2015. That overall market generated $20.3bn in 2010, according to Small-Molecule Targeted Cancer Therapies: World Market 2011-2021, published in October 2011.

Worldwide, more than 13 million patients were diagnosed with cancer in 2009; there may be 20 million new cases annually by 2025. Dr Syed Ahmed, a senior healthcare industry analyst at visiongain, said: "The number of cancer-related deaths is very significant. There is still an under-met need for therapeutic agents that not only prolong the survival of cancer patients but also greatly enhance their quality of life. Anti-cancer drugs - including small-molecule targeted cancer therapies - will remain a crucial part of the pharmaceutical market from 2011 to 2021."

Targeted cancer therapies are agents that block the growth and spread of cancer by interfering with molecules involved in tumour growth and progression. Most targeted therapies are either small-molecule drugs or monoclonal antibodies. Unlike antibody therapies, small-molecule targeted cancer drugs pass through cell membranes to reach targets inside the cell.

The report analyst added: "The market for small-molecule targeted cancer therapies is dominated by a number of blockbuster drugs led by Novartis' Glivec/Gleevec. Some of these products are due to lose patent protection this decade, offering opportunities for generic competitors. Nevertheless, a strong R&D pipeline for small-molecule cancer therapies makes this industry segment dynamic and promising for pharmaceutical companies."

Visiongain forecasts that the overall market for small-molecule targeted cancer therapies will grow steadily to 2021. Rising disease prevalence, along with advances in pharmacotherapy and diagnostics, will stimulate the small-molecule cancer drug market, the report concludes. This new study adds to visiongain's wide range of analytical reports on healthcare and other industries.

To view report sample pages please click on:

http://www.visiongain.com/Report/708/Small-Molecule-Targeted-Cancer-Therapies-World-Market-2011-2021

To request an exec summary please email Sara Peerun
Email: sara.peerun@visiongainglobal.com
Tel: +44-0207-336610
Web: http://www.visiongain.com

Table of Contents
1. Executive Summary
1.1 Overview of Findings
1.2 Scope and Format of the Report
1.3 Research and Analysis Methods

2. Introduction: Cancer, its Physiology, Burden and Treatment
2.1 Targeted Cancer Therapies
2.2 The Physiology of Cancer
2.2.1 Uncontrolled Growth
2.2.2 Dedifferentiation
2.2.3 Invasiveness and Metastasis
2.2.4 Causes of Cancer
2.3 Incidence and Mortality for Cancer
2.3.1 Incidence
2.3.2 Mortality
2.3.3 Survival
2.3.3.1 The Developed World
2.3.3.2 The Developing World
2.4 Treating Tumours
2.4.1 Chemotherapy
2.4.2 Traditional Antineoplastics
2.4.3 Novel Antineoplastics
2.4.3.1 Kinase Receptor Antagonists
2.4.3.2 Other Novel Antineoplastics
2.4.4 Hormone Therapies
2.4.5 Active Immunotherapy
2.4.6 Passive Immunotherapy: Monoclonal Antibodies
2.5 Small-Molecule Targeted Cancer Therapies
2.5.1 Signal Transduction Inhibitors
2.5.2 Gene Expression and Other Cellular Function Regulators
2.5.3 Small-Molecule Apoptotic Inducing Drugs
2.5.4 Angiogenesis Blockers
2.6 Targeted Cancer Therapies: Small-Molecule Drugs

3. The Small-Molecule Cancer Therapies Market, 2011-2021
3.1 The World Small-Molecule Cancer Therapies Market in 2010
3.2 Growing Market for Small-Molecule Cancer Therapies
3.2.1 Sales Forecast for Small-Molecule Cancer Therapies, 2011-2015
3.2.2 Sales Forecast for Small-Molecule Cancer Therapies, 2016-2021
3.3 Leading Products in Small-Molecule Cancer Therapies Market

4. Small-Molecule Cancer Therapies: Leading National Markets, 2011-2021
4.1 The US Small-Molecule Cancer Therapies Market, 2011-2021
4.2 The Japanese Small-Molecule Cancer Therapies Market, 2011-2021
4.3 The Leading European Small-Molecule Cancer Therapies Markets, 2011-2021
4.4 Emerging-Economy Small-Molecule Cancer Therapies Markets
4.5 The Chinese Small-Molecule Cancer Therapies Market, 2011-2021
4.6 The Indian Small-Molecule Cancer Therapies Market, 2011-2021
4.7 Summary of Market Forecasts

5. Leading Small-Molecule Anti-Cancer Products, 2011-2021
5.1 Glivec/Gleevec (Novartis)
5.1.1 Glivec/Gleevec Sales 2010
5.1.2 Glivec/Gleevec Sales Forecast, 2011-2015
5.1.3 Glivec/Gleevec Sales Forecast, 2016-2021
5.1.4 Tasigna Set to Replace Glivec/Gleevec
5.2 Revlimid (Celgene)
5.2.1 Revlimid Sales 2010
5.2.2 Secondary Malignancies
5.2.3 Revlimid Sales Forecast, 2011-2015
5.2.4 Revlimid Sales Forecast, 2016-2021
5.3 Alimta (Eli Lilly)
5.3.1 Alimta Sales 2010
5.3.2 Patent Disputes
5.3.3 Alimta Sales Forecast, 2011-2015
5.3.4 Alimta Sales Forecast, 2016-2021
5.4 Taxotere (Sanofi)
5.4.1 Taxotere Sales 2010
5.4.2 Patent Expiry
5.4.3 Taxotere Sales Forecast, 2011-2015
5.4.4 Taxotere Sales Forecast, 2016-2021
5.5 Velcade (Takeda/J&J)
5.5.1 Velcade Sales 2010
5.5.2 Recent Developments
5.5.3 Velcade Sales Forecast, 2011-2015
5.5.4 Velcade Sales Forecast, 2016-2021
5.6 Arimidex (AstraZeneca)
5.6.1 Arimidex Sales 2010
5.6.2 Patent Expiry
5.6.3 Arimidex Sales Forecast, 2011-2015
5.6.4 Arimidex Sales Forecast, 2016-2021
5.7 Tarceva (Roche)
5.7.1 Tarceva Sales 2010
5.7.2 Patent Expiry
5.7.3 Tarceva Sales Forecast, 2011-2015
5.7.4 Tarceva Sales Forecast, 2016-2021
5.8 Sutent (Pfizer)
5.8.1 Sutent Sales 2010
5.8.2 Generic Launch Expected for Sutent
5.8.3 Sutent Sales Forecast, 2011-2015
5.8.4 Sutent Sales Forecast, 2016-2021
5.8.5 Additional Indication Approval.
5.8.6 Late-Stage Clinical Trials for Additional Uses and Dosage Forms for Sutent
5.9 Nexavar (Bayer/Onyx)
5.9.1 Nexavar Sales 2010
5.9.2 Patent Expiry
5.9.3 Nexavar Sales Forecast, 2011-2015
5.9.4 Nexavar Sales Forecast, 2016-2021
5.10 Sprycel (Bristol-Myers Squibb)
5.10.1 Sprycel Sales 2010
5.10.2 Patent Expiry
5.10.3 Sprycel Sales Forecast, 2011-2015
5.10.4 Sprycel Sales Forecast, 2016-2021

6. R&D Pipeline for Small-Molecule Cancer Products
6.1 An Overview
6.2 Small-Molecule Lung Cancer Pipeline 2011
6.2.1 BIBW 2992 (Boehringer Ingelheim)
6.2.2 Crizotinib (Pfizer)
6.3 Small-Molecule Breast Cancer Pipeline 2011
6.3.1 Line Extensions
6.3.2 Halaven (Eisai)
6.4 Small-Molecule Colorectal Cancer Pipeline 2011
6.4.1 BAY 73-4506 (Bayer)
6.4.2 KRX 0401 (Keryx/Aeterna Zentaris)
6.5 Small-Molecule Stomach Cancer Pipeline 2011
6.5.1 Line Extensions
6.5.2 Telatinib (ACT Biotech)
6.6 Small-Molecule Prostate Cancer Pipeline 2011
6.6.1 MDV 3100 (Astellas/Medivation)
6.6.2 CB7630 (Centocor Ortho Biotech)
6.7. Small-Molecule Multiple Myeloma Pipeline, 2011
6.7.1 Proteasome Inhibitors: the Next Generation
6.7.1.1 CEP 18770 (Cephalon)
6.7.1.2 Marizomib (Nereus)
6.7.1.3 MLN 9708 (Takeda)
6.7.1.4 CEP 28331 (Cephalon)
6.7.2 Immunomodulators: the Past or the Future for Myeloma Treatment?
6.7.2.1 Afinitor (Novartis)
6.7.2.2 E-Selectin Antagonists (GlycoMimetics)
6.7.3 Histone Deacetylase Inhibitors: An Important New Sector
6.7.3.1 Istodax (Celgene Corporation)
6.7.3.2 Zolinza (Merck & Co.)
6.7.3.3 AR 42 (Arno)
6.7.3.4 Givinostat (Italfarmaco)
6.7.3.5 HDAC6 Inhibitors (Acetylon)
6.7.4 Kinase Inhibitors/Signal Transduction Blockers: The Largest Pipeline Sector
6.7.4.1 Votrient (GlaxoSmithKline)
6.7.4.2 Lenocta (VioQuest)
6.7.4.3 Ruxolitnib (Novartis)
6.7.4.4 Lestaurtnib (Cephalon)
6.7.4.5 Masitnib (AB Science)
6.7.4.6 AT 9283 (Astex Therapeutics)
6.7.4.7 Dovitnib (Novartis)
6.7.4.8 P276 (Piramal Life Sciences)
6.7.4.9 PD332991 (Pfizer)
6.7.4.10 ENMD 2076 (EntreMed)
6.7.4.11 AT 7519 (Astex Therapeutics)
6.7.4.12 MLN 8237 (Takeda)
6.7.4.13 Estybon (Onconova)
6.7.4.14 CX 4945 (Cylene)
6.7.4.15 GDC 0941 (Roche)
6.7.4.16 INK 128 (Intellikine)
6.7.4.17 SF 1126 (Semafore)
6.7.4.18 SNS 032 (Sunesis/Bristol-Myers Squibb)
6.7.4.19 Sprycel (Otsuka/Bristol-Myers Squibb)
6.7.4.20 TG 02 (Tragara/S*BIO)
6.7.4.21 R763 (Rigel)
6.7.5 Heat Shock Protein Modulators
6.7.5.1 AUY 922 (Novartis)
6.7.5.2 KW 2478 (Kyowa Hakko Kirin)
6.7.5.3 NVP BEP800 (Novartis)
6.7.6 Apoptosis Inducers: Four Products at Phase II
6.7.6.1 GCS 100 (Prospect Therapeutics)
6.7.6.2 Amplimexon (AmpliMed )
6.7.6.3 Trisenox (Nippon Shinyaku)
6.7.6.4 Noscapine (Cougar Biotechnology)
6.7.6.5 BMS 833923 (Bristol-Myers Squibb)
6.7.6.6 SNS 01-T (Senesco)
6.7.7 Other Small-Molecule Myeloma Products
6.7.7.1 Products in Phase II
6.7.7.2 Amnolake (CytRx)
6.7.7.3 Coprexa TM (Attenuon)
6.7.7.4 Brostallacin (Cell Therapeutics)
6.7.7.5 CYT 997 (YM BioSciences)
6.7.7.6 ARRY 520 (Array BioPharma)
6.7.7.7 Zinapar (Ziopharm)
6.7.7.8 Products in Phase I
6.7.7.9 Quadramet (EUSA Pharma)
6.7.7.10 LC1 (Leuchemix)
6.7.7.11 MLN 4924 (Takeda)
6.7.7.12 OPB 31121 (Otsuka)
6.7.7.13 Zalypsis (PharmaMar)
6.7.7.14 Products in Preclinical Studies
6.7.7.15 INNO 206 (CytRx)
6.7.7.16 Ostabolin-C (Zelos)
6.7.7.17 IRE1-alfa inhibitor (Mannkind)
6.7.7.18 HIF Signalling Inhibitors (Elara)
6.7.7.19 PS 031291 (Ligand)
6.7.7.20 SST 0001 (Sigma-Tau)
6.7.7.21 CGEN 928 (Compugen)
6.7.7.22 USP7 Inhibitors (Progenra)
6.8 Small-Molecule Epigenetic Therapy Pipeline, 2011
6.8.1 HDAC Inhibitors
6.8.1.1 PXD-101 (Belinostat, TopoTarget/Spectrum Pharmaceuticals)
6.8.1.2 LBH589 (Panobinostat, Novartis)
6.8.1.3 Entinostat (Syndax Pharmaceuticals)
6.8.1.4 4SC-201 (Resminostat, 4SC)
6.8.1.5 MGCD-0103 (Mocetinostat, MethylGene)
6.8.1.6 SB939 (S*BIO)
6.8.1.7 ACY-1215 (Acetylon Pharmaceuticals)
6.8.1.8 Valproic Acid
6.8.2 DNMT Inhibitors
6.8.2.1 SGI-110 (Astex Pharmaceuticals)
6.8.2.2 CP-4200 (Clavis Pharma)

7. Qualitative Analysis of the Small-Molecule Cancer Therapies Market, 2011-2021
7.1 SWOT Chart for Small-Molecule Cancer Therapies Market 2011-2021
7.2 Strengths
7.2.1 Cancer Treatment has Proven Commercial Potential
7.2.2 High Profile Nature of Cancer
7.2.3 Off-Label Prescriptions are Common
7.2.4 Strong Drug Development Incentives
7.3 Weaknesses
7.3.1 Tumours and Multidrug Resistance (MDR)
7.3.2 Pricing-Out the Developing World?
7.4 Opportunities
7.4.1 Cancer is a Key Business Area for the Pharmaceutical Industry
7.4.2 Rising Incidence of Cancer
7.4.1.1 Aging Populations
7.4.1.2 Smoking
7.4.1.3 Obesity
7.4.1.4 The Developing World
7.4.3 Greater Understanding of Cancer Biology Gives Opportunities in the Cancer Treatment Industry
7.4.4 Advanced Diagnostics with Pharmacogenomics: Impact on Cancer Therapies
7.4.5 Live Licensing and In-Life Testing
7.4.6 Convenience of Targeted Drugs versus Chemotherapy
7.5 Threats
7.5.1 Healthcare Spending Restraints Threaten Cancer Drug Revenues
7.5.2 The Cost-Effectiveness Debate
7.5.3 Governments are a Leading Payer for Drugs
7.5.4 Efficacy, Toxicity and Alternative Treatments
7.6 Biosimilars and Generics: Opportunity or Threat?
7.7 Personalised Medicine and Cancer
7.7.1 Biomarkers and Diagnostics
7.7.2 Small-Molecule (Metabolic) Biomarkers
7.7.3 Cancer Heterogeneity
7.7.4 Pharmacogenomics
7.7.5 Genome Screening
7.7.6 Theranostics

8. Research Interviews
8.1 Dr Martin Bonde, CEO, EpiTherapeutics
8.1.1 Potential for Histone Methyltransferase Inhibitors
8.1.2 Future of Epigenetics Research
8.1.3 Histone Methyltransferase Inhibitors on Market within Decade?
8.1.4 Challenges in Developing Epigenetic Therapies
8.1.5 Benefits of University Spin-Outs
8.2 Dr Joanna Horobin, President and CEO, Syndax Pharmaceuticals
8.2.1 On Challenges Facing Cancer Therapies
8.2.2 On Selective Targeting of Therapies
8.2.3 On Drug Resistance and Targeted Therapies
8.2.4 On Drug Resistance and Market Opportunity
8.2.5 On Entinostat, Lung and Breast Cancer Therapies

9. Conclusions
9.1 Small-Molecule Cancer Therapies Market Offers Promise
9.2 Leading Products in Small-Molecule Cancer Therapies Market, 2010
9.3 The US Will Remain the World's Largest Small-Molecule Cancer Therapies Market
9.4 India and China Will be the Fastest-Growing National Markets
9.5 R&D Pipelines for Many Cancer Types Are Strong
9.6 Concluding Remarks

Companies Listed
4SC
AB Science
Abbott Laboratories
Abgenix
Abraxis BioScience
Acceleron
Ascenta Therapeutics
Acetylon
Actavis
ACT Biotech
Active Biotech
Adeona
AERES Biomedical
Aeterna Zentaris
Agennix
Alexion
Alza
Allos Therapeutics
American Society of Clinical Oncology (ASCO)
American Society of Hematology (ASH)
Amgen
AmpliMed
Anthrogenesis
Apexigen
Apotex
APP Pharmaceuticals (part of the Fresenius Kabi Group)
ARIAD Pharmaceuticals
Arizona University
Arno
Array BioPharma
Ascenta Therapeutics
Astellas Pharma
Astex Therapeutics
AstraZeneca
Attenuon
AVEO Pharmaceuticals
Barr Laboratories
Bayer
Biogen Idec
BioInvent
Bionovo
Biotech Research and Innovation Centre (BRIC), University of Copenhagen
Biotest
BioWa
BiPar Sciences (subsidiary of Sanofi)
Boehringer Ingelheim
Bristol-Myers Squibb
British Biotech
BTG
Canadian National Research Council
Cancer Research Technology
Cancer Research UK
Cancer Science Institute of Singapore (CSI Singapore)
Celanese
Celgene
Cell Therapeutics
Centocor Ortho Biotech
Cephalon
Cetus Corporation
Chiron
Choongwae
Cipla
Clavis Pharma
Cleveland Clinic
Columbia University
Compugen
Concordia Pharmaceuticals
Constellation Pharmaceuticals
Cougar Biotechnology
Crinos
CTI Technologies
CuraGen
CureVac
Cyclacel Pharmaceuticals
CyDex
Cylene
Cytogen
Cytokinetics
CytRx
Daiichi Sankyo
Dako
Dana Farber Cancer Institute
Endocyte
Elan
EntreMed
Dendreon
Dr. Reddy's Laboratories
Eisai
Elara Pharmaceuticals
Eleison Pharmaceuticals
Eli Lilly
European Medicines Agency (EMEA/EMA)
European Molecular Biology Laboratory
Endocyte
EntreMed
EpiTherapeutics
Epizyme
EUSA Pharma
Exelixis
Facet Biotech
Food and Drug Administration (US FDA)
Fresenius Kabi
Genentech (now part of Roche)
Generex Biotechnology
Genmab
Genta
Genzyme
Geron
GlaxoSmithKline (GSK)
Gloucester Pharmaceuticals
GlycoGenesys
GlycoMimetics
GPC Biotech
Greenwich Therapeutics
GTC Biotherapeutics
Handok
Harvard University
Hospira
Human Genome Sciences
IkerChem
ILEX Oncology
ImClone Systems (a subsidiary of Eli Lilly)
Immune System Therapeutics
ImmunoGen
Incyte
Infinity Pharmaceuticals
Innate Pharma
Intas Biopharmaceuticals
Intellikine
International Cancer Genome Consortium
International Myeloma Working Group
Introgen Therapeutics
Isis Pharmaceuticals
Italfarmaco
Janssen-Cilag
Johnson & Johnson (J&J)
Kaken
Karyopharm Therapeutics
Keryx Biopharmaceuticals
Keyaku Zentaris
Kosan Biosciences
Kyowa Hakko Kirin
Leuchemix
Les Laboratoires Servier
Ligand
Lipomed
Lonza
Mannkind
Marlborough Research and Development
Marshall Edwards
MD Anderson Cancer Center
MedImmune
Medivation
Merck & Co.
Merck KGaA
Merck Serono (part of Merck KGaA)
MethylGene
Micromet
Millennium Pharmaceuticals
MorphoSys
Mount Sinai Medical Center [US]
Multiple Myeloma Research Consortium
Multiple Myeloma Research Foundation
Mylan
Natco Pharma
National Cancer Institute (NCI) [US]
National Cancer Institute (US)
National Health Service (NHS) [UK]
National Institute for Clinical Excellence (NICE) [UK]
National University Cancer Institute Singapore (NCIS)
NCIC Clinical Trials Group
Nektar Therapeutics
Nereus
Nerviano Medical Sciences
Nippon Shinyaku
Novartis
Novo Nordisk
Novogen
Ohio State University
OncoGenex Pharmaceuticals
Oncova
Ono Pharmaceuticals
Onyx Pharmaceuticals
Ortho Biotech
Otsuka
Oxford University
Par Pharmaceutical
PDL BioPharma
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA) [US]
Pharmacia
Pharmacopeia
Pharmacyclics
PharmaMar
Pharmion
Pierre Fabre
Pipex
Piramal Life Sciences
PIramed
PolaRx Biopharmaceuticals
Poniard Pharmaceuticals
Proacta
Progenra
Prospect Therapeutics
Protein Design
Proteolix
R&R
Radient Pharmaceuticals
Regeneron
Rigel
Roche
Rockefeller University
Roxane Laboratories
Salk Institute for Biological Studies
S*BIO
Sandoz (part of Novartis)
Sanofi (sanofi-aventis)
Scancell
Schering-Plough
Scripps Institution of Oceanography
Seattle Genetics
Semafore
Senesco
Shire
Sigma-Tau
Signal Pharmaceuticals
Sirton
Sloan-Kettering Institute
Spectrum Pharmaceuticals
Stada Arzneimittel
Sun Pharmaceuticals
Sunesis
Syndax Pharmaceuticals
Taiho Pharma
Takeda
Tapestry Pharmaceuticals
TargeGen
Teva Pharmaceutical Industries
Texas A&M University
Threshold Pharmaceuticals
TMRC
Toko
TopoTarget
Tragara
Tufts University
University of Basel PharmaCenter (PharmaCenter Basel)
University of Cambridge
University of Kentucky College of Pharmacy
University of Michigan
University of San Diego
US National Comprehensive Cancer Network
Vernalis
VioQuest
Wayne State University
WILEX
World Health Organization (WHO)
Xencor
XOMA
XTL Biopharmaceuticals
Yakult Honsha
Yeda Research and Development Company
YM Biosciences
Zelos
Zeltia
Zenyaku Kogyo
Zeria
Ziopharm 

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Telecoms, Energy, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. 

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100